Discovery of Natural SGLT2-Inhibitors for Type 2 Diabetes – Possible Way to Reduce Side Effects

Jump To References Section

Authors

  • ,IN
  • ,ZA

DOI:

https://doi.org/10.18311/jnr/2015/727

Keywords:

Antihyperglycemic drugs, Dapagliflozin, Insulin, Renal glucose, Sodium-Glucose Co-Transporter 2.
Therapeutic Drug Monitoring

Abstract

The number of patients diagnosed with diabetes mellitus in all over the world has risen ominously in the past few decades, in which majority of cases belongs to type 2 diabetes. Previously, type 2 diabetes was known as adult-onset and noninsulin-dependent but now it can be seen at any stage including childhood. Various recent researches revealed that type 2 diabetes can be treated by inhibiting sodium-glucose co-transporter 2 (SGLT2), a protein which facilitates glucose reabsorption in the kidney. SGLT2 inhibitors can reduce the blood sugar level by blocking reabsorption of glucose in the kidney and increasing glucose excretion. In the past couple of years, many SGLT2 inhibitors have been discovered but owing to serious side effects, their use is completely banned. Hence, the discovery of natural SGLT2 inhibitors can be helpful in treating type 2 diabetes without any adverse effects.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2016-02-09

How to Cite

Semwal, D. K., & Semwal, R. B. (2016). Discovery of Natural SGLT2-Inhibitors for Type 2 Diabetes – Possible Way to Reduce Side Effects. Journal of Natural Remedies, 15(2), 86–87. https://doi.org/10.18311/jnr/2015/727
Received 2016-01-13
Accepted 2016-01-19
Published 2016-02-09

 

References

Moses RG. Combination therapy for patients with type 2 Diabetes: Repaglinide in combination with metformin.Expert Rev Endocrinol Metab. 2010; 5:331–42.

Semwal DK, Rawat U, Semwal R, Singh R, Singh GJ. Antihyperglycemic effect of 11-hydroxypalmatine, a palmatine derivative from stephania glabra tubers. J Asian Nat Prod Res. 2010; 12:99–105.

Valentine V. The role of the kidney and sodium-glucose cotransporter-2 inhibition in diabetes management.Clinical Diabetes. 2012; 30:151–5.

Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013; 12:153–75.

Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus:A meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013; 13:58.

Cuypers J, Mathieu C, Benhalima K. SGLT2-inhibitors: A novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg.2013; 68:287–93.